Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 31, Issue 6, 2011, Pages 735-740

  Liu, Dong ^a   Xu, Yanjiao ^a   Rao, Zichao ^a   Chen, Zhaocong ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Anti HER2 monoclonal antibody; Immunoconjugate; Paclitaxel; Specific binding

Indexed keywords

ANTIBODY CONJUGATE; CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PACLITAXEL;

ARTICLE; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOCONJUGATES; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTOR, ERBB-2;

EID: 84862947796     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-011-0669-8     Document Type: Article

References (22)

1. Jaracz S, Chen J, Kuznetsova LV, et al. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem, 2005,13(17):5043-5054 (Pubitemid 41039965)
2. Zhao J, Cao SL, Zheng XL, et al. Folate receptor- mediated antitumor drugs. Yaoxue Xuebao (Chinese), 2009,44(9): 109-114
3. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther, 2004,3(4):361-370 (Pubitemid 41350865)
4. Camilleri BS, Hardy-Bessard AC, Le TA, et al. HER2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: A multicenter study of the gineco group. Ann Oncol, 2004,15(1): 104-122
5. Cao Y, Marks JD, Marks JW, et al. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: In vitro and in vivo studies. Cancer Res, 2009,69(23):8987-8995
6. Mandler R, Kobayashi H, Hinson ER, et al. Herceptin- geldanamycin immunoconjugates: Pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res, 2004,64(4):1460-1467
7. Chen H, Gao J, Lu Y, et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release, 2008,28(3): 209-216
8. Moliterni A, Menard S, Valagussa P, et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for respectable breast cancer. J Clin Oncol, 2003,21(3):458-462 (Pubitemid 46606475)
9. Junttila TT, Tanner M, Isola J. Targeted cytotoxic drugs emerging for cancer therapy. Duodecim, 2011,127(4): 343-349
10. Fu Y, Li S, Zu Y, et al. Medicinal chemistry of paclitaxel and its analogues. Curr Med Chem, 2009,16(30): 3966-3985
11. Schrader C, Keussen C, Bewig B, et al. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res, 2005,10(11):498-501 (Pubitemid 41723599)
12. Cruz A, Temu T, Hines-Telang G, et al. Paclitaxel- induced neutrophilic adverse reaction and acral erythema. Acta Derm Venereol, 2011,91(1):86-87
13. Rao SC, Chu JJ, Liu RS, et al. Synthesis and evaluation of [14C]-labelled and fluorescent-tagged paclitaxel derivatives as new biological probes. Bioorg Med Chem, 1998,6(11):2193-2204
14. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem, 2010,21(1):84-92
15. Burke PJ, Toki BE, Meyer DW, et al. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-paminobenzyl- amine linker system. Bioorg Med Chem Lett, 2009,19(1):2650-2653
16. Safavy A, Bonner JA, Waksal HW, et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem, 2003,14(2):302-310 (Pubitemid 36348653)
17. Liu D, Rao ZCh, Chen ZhC, et al. Killing effect of anti-HER2 monoclonal antibody-TAX immunoconjugate on the tumor cells in vitro. Chin Hosp Pharm J (Chinese), 2007,27(1):10-13
18. Gao Y, Wu Q, Liang X, et al. Effect of anti-HER-2 engineered antibody chA21 on MMP-2 and TIMP-2 expression of human ovarian cancer SKOV3 cells. J Si'An Jiaotong Univ (Medical Sci), 2007,28(4):368-371
19. Huang SS, Liu R, Qu YX, et al. Fluorescent biological label for recognizing human ovarian tumor cells based on fluorescent nanoparticles. J Fluoresc, 2009,19(6):1095-1101
20. Sun Y, Yu F, Sun BW, et al. Antibody-drug conjugates as targeted cancer therapeutics. Yaoxue Xuebao (Chinese), 2009,44(9):943-952
21. Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol, 1999,26(4 Suppl 12):41-50 (Pubitemid 29411432)
22. Martin CG. Targeted drug conjugates: Principles and progress. Adv Drug Deliv Rev, 2001,53(2):172-216